Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition.


Journal

Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105

Informations de publication

Date de publication:
07 2020
Historique:
received: 21 01 2020
revised: 14 02 2020
accepted: 15 02 2020
pubmed: 7 3 2020
medline: 9 9 2020
entrez: 6 3 2020
Statut: ppublish

Résumé

A hallmark of ductal carcinoma in situ (DCIS) progression is a loss of the surrounding ductal myoepithelium. However, whether compromise in myoepithelial differentiation, rather than overt cellular loss, can be used to predict the risk of DCIS progression is unknown. Here we address this question utilizing pure and mixed DCIS cases (N = 30) as surrogates for DCIS at low and high risk for progression, respectively. We used multiplex immunohistochemical staining to evaluate the relationship between myoepithelial cell differentiation and lymphoid immune cell types associated with poor prognostic DCIS. Our results show that myoepithelial calponin-1 discriminates between pure and mixed DCIS lesions better than histological subtype, presence of necrosis, or nuclear grade. Additionally, focal loss of myoepithelial cells associated with increased PD-1+CD8+ T cells, which suggests a link between the myoepithelium and immune surveillance. To identify associations between calponin-1 expression and immune response, we performed unsupervised hierarchical clustering of myoepithelial and immune cell biomarkers on 219 DCIS lesions from 30 cases. Notably, the majority of pure (low-risk) DCIS lesions clustered in a high calponin-1, T cell low group, whereas the majority of mixed (high-risk) DCIS lesions clustered in a low calponin-1, T cell high group, specifically with CD8+ and PD-1+CD8+ T cells. However, a subset of pure DCIS lesions had a similar calponin-1 and immune signature as the majority of mixed DCIS lesions, which have low calponin-1 and T cell enrichment-raising the possibility that these pure DCIS lesions might be at a high risk for progression.

Identifiants

pubmed: 32134153
doi: 10.1002/mc.23171
pmc: PMC7317523
doi:

Substances chimiques

Biomarkers, Tumor 0
Calcium-Binding Proteins 0
Microfilament Proteins 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-712

Informations de copyright

© 2020 The Authors. Molecular Carcinogenesis published by Wiley Periodicals LLC.

Références

Biomaterials. 2019 Nov;221:119407
pubmed: 31442697
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
Rev Bras Ginecol Obstet. 2013 Mar;35(3):97-102
pubmed: 23538467
Breast Cancer Res Treat. 2018 Feb;167(3):787-795
pubmed: 29119353
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:672-675
pubmed: 29059962
Anticancer Res. 2014 Nov;34(11):6363-80
pubmed: 25368236
J Pathol. 2011 Jan;223(2):307-17
pubmed: 21125683
Breast J. 2015 Jul-Aug;21(4):377-86
pubmed: 25879521
J Biol Chem. 1990 Jun 15;265(17):10148-55
pubmed: 2161834
Mod Pathol. 2016 Mar;29(3):249-58
pubmed: 26769139
Clin Cancer Res. 2017 Sep 1;23(17):5210-5217
pubmed: 28611201
Am J Clin Pathol. 2016 Jul;146(1):137-44
pubmed: 27402610
Nat Genet. 2003 Jan;33(1):49-54
pubmed: 12469122
Breast Dis. 2015;35(4):249-52
pubmed: 26397772
Cancer Cell. 2004 Jul;6(1):17-32
pubmed: 15261139
J Cell Biochem. 2017 Mar;118(3):518-529
pubmed: 27579780
J Pathol. 2003 Dec;201(4):562-72
pubmed: 14648659
Breast Cancer Res. 2013 Jun 28;15(3):206
pubmed: 23826974
Breast Cancer Res Treat. 2012 Jun;133(3):889-98
pubmed: 22052326
Mod Pathol. 2015 May;28(5):662-9
pubmed: 25502729
CA Cancer J Clin. 2015 Nov-Dec;65(6):481-95
pubmed: 26431342
Cancer Sci. 2005 Nov;96(11):738-46
pubmed: 16271067
Cell. 2018 Jan 11;172(1-2):205-217.e12
pubmed: 29307488
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cancer Detect Prev. 2005;29(4):323-31
pubmed: 16122886
Am J Pathol. 2015 Nov;185(11):3076-89
pubmed: 26343330
Exp Mol Pathol. 2003 Apr;74(2):113-22
pubmed: 12710942
Breast Cancer Res. 2008;10(5):R87
pubmed: 18928525
JCI Insight. 2017 Mar 23;2(6):e89206
pubmed: 28352652
J Exp Med. 1989 Nov 1;170(5):1595-608
pubmed: 2509626
Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:796-799
pubmed: 30364524
Nat Commun. 2019 Sep 13;10(1):4182
pubmed: 31519911
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Cancer Discov. 2017 Oct;7(10):1098-1115
pubmed: 28652380
Med Hypotheses. 2007;69(6):1340-57
pubmed: 17493765
Breast Cancer Res Treat. 2016 Jun;157(2):351-361
pubmed: 27146587
Mol Carcinog. 2020 Jul;59(7):701-712
pubmed: 32134153
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
pubmed: 12714683
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
Oncotarget. 2015 Dec 22;6(41):43244-54
pubmed: 26657114
Cancer Res. 2015 Sep 15;75(18):3980-90
pubmed: 26249178
Cancer Cell. 2008 May;13(5):394-406
pubmed: 18455123
Exp Cell Res. 2004 Dec 10;301(2):103-18
pubmed: 15530847
Breast Cancer Res. 2017 Mar 23;19(1):33
pubmed: 28330493
JAMA Oncol. 2015 Oct;1(7):888-96
pubmed: 26291673
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7
pubmed: 19218449
JAMA Oncol. 2016 Aug 1;2(8):1083-8
pubmed: 27253401
Cancer. 1995 Oct 1;76(7):1197-200
pubmed: 8630897
Breast Cancer Res. 2017 May 15;19(1):56
pubmed: 28506312
Breast Cancer Res. 2009;11(1):101
pubmed: 19291276
Breast Cancer Res Treat. 2017 Jan;161(1):17-28
pubmed: 27785654
Clin Breast Cancer. 2019 Oct;19(5):e617-e623
pubmed: 31101455
Breast Cancer Res Treat. 2005 Jan;89(2):199-208
pubmed: 15692763
J Cell Biol. 2018 Oct 1;217(10):3368-3381
pubmed: 30061105
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Histopathology. 2017 Aug;71(2):258-268
pubmed: 28326600
Clin Chem. 2014 Jan;60(1):60-7
pubmed: 24262106
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
J Pathol. 2017 Dec;243(4):496-509
pubmed: 29086922
Breast Cancer Res. 2005;7(5):190-7
pubmed: 16168137
Cancer Med. 2016 Jul;5(7):1607-18
pubmed: 27061242
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Elizabeth Mitchell (E)

Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.

Sonali Jindal (S)

Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Cancer Prevention and Control, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

Tiffany Chan (T)

Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.

Jayasri Narasimhan (J)

Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.

Shamilene Sivagnanam (S)

Computational Biology Program, Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.

Elliot Gray (E)

Department of Biomedical Engineering, Oregon Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, Oregon.

Young Hwan Chang (YH)

Department of Biomedical Engineering, Oregon Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, Oregon.

Sheila Weinmann (S)

Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.

Pepper Schedin (P)

Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Cancer Prevention and Control, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH